Please assess the completion status of the following clinical trial:

Trial Title: Antipsychotic Discontinuation in Alzheimer's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Dementia, either sex, age 50-95 years~* Probable Alzheimer's disease~* Intellectual impairment present for at least 6 months~* Mini Mental State Exam (MMSE) score of 5-26 for outpatients and 2-26 for nursing home patients~* Availability of informant who has had direct contact with the patient for an average of at least once every week during the 3 months prior to study entry~* Meets Neuropsychiatric Inventory (NPI) criteria for either (1) psychosis, or (2) agitation/aggression~* Able to mobilize independently (if wheelchair-bound, the patient must be able to self-propel)~* Free of psychotropic medication (or able to tolerate washout) for at least 1 week prior to study entry. Low dose antidepressants and sedative/hypnotics allowed if they cannot be washed out and the dose remains stable for the study duration~* Expected to complete the study (including all efficacy evaluations) and be without major sensory impairment that would prevent participation in any aspect of the study~Exclusion Criteria:~* Current primary Axis I psychiatric disorder other than AD~* Substance abuse or dependence currently, or within the past year~* Dementia due to head trauma~* History of allergy to risperidone or intolerance to risperidone~* Diffuse Lewy body disease~* History of seizure disorder, infectious encephalitis, Parkinson's disease, central nervous system (CNS) neoplasm, tardive dyskinesia, stroke, transient ischemic attack (TIA) or uncontrolled atrial fibrillation~* Use of monoamine oxidase inhibitors (MAOIs) and unable to undergo 3-week washout; patients also may not take MAOIs for 2 weeks after completing the study~* In treatment with (a) depot antipsychotic within 2 weeks of the screening visit~* Untreated or incompletely treated hypothyroidism~* Active, unstable medical condition that requires active medication adjustment or surgery~* Need for electroconvulsive treatment (ECT)~* Significant risk for harm to themselves or others as a result of randomization to placebo~* History of malignant neoplasm during the last 5 years

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 95 Years
- Healthy Volunteers: f

Study Arms:
- Risperidone-risperidone (Type: OTHER): Risperidone for 16 weeks followed by risperidone for 16 weeks
- Risperidone-Placebo (Type: OTHER): Risperidone for 16 weeks followed by placebo for 16 weeks
- Placebo-Placebo (Type: OTHER): Placebo for 16 weeks followed by placebo for 16 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).